60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development...
The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island...
WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60...
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized...
With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for...
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that...
Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent...
Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand.Gross profit increased from...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.